Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 2437
IPSCIO Record ID: 2427
IPSCIO Record ID: 26203
Zaleplon (being N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide)
Botulinum Toxin Type B
Metaxalone is a muscle relaxant used to relax muscles and relieve pain caused by strains, sprains, and other musculoskeletal conditions.
Zaleplon is a sedative-hypnotic, almost entirely used for the management/treatment of insomnia.
Antegren is a humanized monoclonal antibody against the cell adhesion molecule a4-integrin. Natalizumab is used in the treatment of multiple sclerosis and Crohn's disease.
Zonisamide is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents.
(a) to the extent required for Elan to comply in all respects with the Orasense Agreements;
(b) to the extent required for Elan to comply in all respects with the Avlan Agreements;
(c) to the extent required for Elan to comply in all respects with the GlycoGenesys Licence Agreement;
(d) to the extent required for Elan to comply in all respects with the Emisphere Settlement Agreement;
(e) to the extent required for Elan to comply in all respects with the Targeted Genetics Agreements; and
(f) with respect to any and all Elan Exclusive Products.